Overview

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Status:
Active, not recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

This study will find out if trastuzumab deruxtecan is safe and works for participants with certain kinds of cancer. They must have HER2-positive gastric or gastro-esophageal junction (GEJ) cancer: - that cannot be removed surgically - that has moved to other parts of the body - that got worse during or after treatment that included trastuzumab The study will enroll about 80 participants. Sites will be in North America and the European Union.

Phase:

Phase 2

Details

Lead Sponsor:

Daiichi Sankyo, Inc.

Collaborator:

AstraZeneca

Treatments:

Trastuzumab